PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics (Paris:ALEHT)(Alternext: ALEHT) today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer’s disease and the EHT 107 program in oncology.
